Psoriasis: Latest Trends in Treatment, Diagnosis and Management in Medical Science

Open Access

Year : 2022 | Volume : | Issue : 2 | Page : 24-32
By

    Dutta Amit Kumar

  1. Kumari Ritu

  1. Associate Professor, Department of Cancer Cytogenetics, Amity Institute of Biotechnology, Amity University, Jharkhand, India
  2. Lab Assistant, Department of Cancer Cytogenetics, Amity Institute of Biotechnology, Amity University, Jharkhand, India

Abstract

Psoriasis is a common chronic inflammatory and autoimmune skin disease that primarily affects the skin. It affects about 2–4% of the world populations. It is clinically characterized by skin rashes, highly inflamed red scale itchy plaque. Abundant therapeutic agents are accessible for the treatment of psoriasis. Wide range of therapeutic mediators such as coal tar, topical corticosteroids, anthralin, retinoid, calcineurin inhibitors, methotrexate, cyclosporine are proven to be effective in treating mild to severe psoriasis. Psoriasis is a lifelong disease and the management, diagnosis and treatment of psoriasis depends on the severity of the disease. Topical therapy is first line treatment of psoriasis management as it has many advantages. For severe conditions, systemic treatment and phototherapy is indicated.

Keywords: Psoriasis, common types, epidemiology, causes, factors, latest treatment

[This article belongs to Research & Reviews : A Journal of Biotechnology(rrjobt)]

How to cite this article: Dutta Amit Kumar, Kumari Ritu Psoriasis: Latest Trends in Treatment, Diagnosis and Management in Medical Science rrjobt 2022; 11:24-32
How to cite this URL: Dutta Amit Kumar, Kumari Ritu Psoriasis: Latest Trends in Treatment, Diagnosis and Management in Medical Science rrjobt 2022 {cited 2022 Aug 30};11:24-32. Available from: https://journals.stmjournals.com/rrjobt/article=2022/view=90152

Full Text PDF Download

Browse Figures

References

1. Sala M, Elaissari A, Fessi H. Advances in Psoriasis Physiopathology and Treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). J Controlled Release. 2016; 239: 182–202p.
2. Liu Y, Krueger JG, Bowcock AM. Psoriasis: genetic associations and immune system changes. Genes and Immunity. 2007; 8(1): 1–2p.
3. Bailey EE, Ference EH, A. Alikhan A, et al. Combination treatments for Psoriasis: A systematic review and meta-analysis. Arch Dermatol. 2012; 148: 511–522p.
4. Lee S, Coleman CI, Limone B, et al. Biologic and non-biologic systemic agents and phototherapy for treatment of chronic plaque psoriasis. Med J Aust. 2006; 185(10): 562– 564p.
5. Henley ND. Rapid-onset skin rash- Guttate psoriasis. American Family Physician. 2012; 86: 361–362p.
6. Syed ZU, Khachemoune A. Inverse psoriasis: Case presentation and review. American Journal of Clinical Dermatology. 2011; 12: 143–146p.
7. Viguier M, Aubin F, Delaporte E, et al. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. Archives of Dermatology. 2012; 148(12): 1423–1425p.
8. Hawilo A, Zaraa I, Benmously R, et al. Erythrodermic Psoriasis: Epidemiological clinical and therapeutic features about 60 cases. La tunisie Medicale. 2011; 89(11): 841–847p.
9. Aydin SZ, Castillo-Gallego C, Ash ZR, et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology. 2012; 225(3): 231–235p.
10. Parisi R, Symmons DP, Griffiths CE, et al. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. Journal of Investigative Dermatology. 2013; 133: 377–385p.
11. Nickoloff BJ. Skin Innate Immune System in Psoriasis: Friend or Foe. Journal of Clinical Investigation. 1999; 104: 1161–1171p.
12. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. New England Journal of Medicine. 1999; 341(24): 1817–1828p.
13. Krueger G, Ellis CN. Psoriasis—recent advances in understanding its pathogenesis and treatment. Journal of the American Academy of Dermatology. 2005; 53(1): 94–100p.
14. Mudigonda P, Mudigonda T, Feneran AN, et al. Interleukin-23 and Interleukin-17: Importance in Pathogenesis and Therapy of Psoriasis. Dermatology Online Journal. 2012; 18(10): 1p.
15. Mease PJ, Armstrong AW. Managing patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of psoriatic Arthritis in patients with psoriasis. Drugs. 2014; 74: 423–441p.
16. Bhutani T, Koo J, Maibach HI. Efficacy of clobetasol spray: factors beyond patient compliance. Journal of Dermatological Treatment. 2012; 23(1): 11– 15p.
17. Nast A, Kopp IB, Augustin M, et al. Evidence based (s3) guidelines for the treatment of psoriasis vulgaris. Journal der deutschen dermatologischen Gesellschaft. 2007; 5(s3): 1–19p.
18. Greaves MW, Weinstein GD. Treatment of Psoriasis. New England Journal of Medicine. 1995; 332(9): 581–589p.
19. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: A Review. Altern Med Rev. 2005; 10(2): 94–111p.
20. Oostveen AM, Beulens CA, Kerkhof PC, et al. The effectiveness and safety of short‐contact dithranol therapy in Paediatric Psoriasis: A prospective comparison of regular day care and day care with telemedicine. British Journal of Dermatology. 2014; 170(2): 454–730p.
21. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. Journal of the American Academy of Dermatology. 1997; 37(1): 85–92p.
22. Martin EG, Sanchez RM, Herrera AE, et al. Topical tacrolimus for the treatment of Psoriasis on the Face, Genitalia, Intertriginous Areas and Corporal Plaques. Journal of Drugs in Dermatology: JDD. 2006; 5(4): 334–336p.
23. Huber C, Christophers E. Kerotolytic effect of salicylic acid. Archives of Dermatological Research. 1977; 257(3): 293–297p.
24. Cordoro KM. Systemic and light therapies for the management of Childhood Psoriasis: part II. Skin Therapy Lett. 2008; 13(4): 1–3p.
25. Holme SA, Anstey AV. Phototherapy and PUVA Photochemotherapy in Children. Photodermatol Photoimmunol Photomed. 2004; 20(2): 69–75p.
26. Lara CI, Ramnarine S, Lansang P. Treatment of childhood psoriasis with Phototherapy and Photochemotherapy. Clin Med Insights Pediatr. 2013; 7: 25–33p.
27. Pasic A, Ceovi R, Lipogenic J, et al. Phototherapy in Pediatric Patients. Pediatr Dermatol. 2003; 20(1): 71–77p.
28. Kopp T, Karlhofer F, Szépfalusi Z, Schneeberger A, Stingl G, Tanew A. Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type. Br J Dermatol. 2004; 151(4): 912–916p.
29. Cordoro KM. Systemic and light therapies for the management of Childhood Psoriasis: part II. Skin Therapy Lett. 2008; 13(4): 1–3p.
30. Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol. 2003; 49(2): 171–182p.
31. Geel van MJ, Mul K, Jager de ME, et al. Systemic treatments in Paediatric Psoriasis: A Systematic Evidence- based Update. J Eur Acad Dermatol Venereol: JEADV. 2015; 29(3): 425–437p.
32. Kalb RE, Strober B, Weinstein G, et al. Methotrexate and Psoriasis: 2009. J Am Acad Dermatol. 2009; 60(5): 824–837p.
33. Wright NA, Piggott CD, Eichenfield LF. The role of biologics and other systemic agents in the treatment of pediatric psoriasis. Semin Cutan Med Surg. 2010; 29(1): 20–27p.
34. Hashkes PJ, Becker ML, Cabral DA, et al. Methotrexate: New uses for an old drug. J Paediatric. 2014; 164(2): 231–236p.
35. Kilic SS, Hacimustafaoglu M, Celebi S, et al. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol. 2001; 18(3): 246–248p.
36. Mahe E, Bodemer C, Pruszkowski A, et al. Cyclosporine in Childhood Psoriasis. Arch Dermatol. 2001; 137(11): 1532–1533p.
37. Ellis CN. Safety issues with cyclosporine. Int J Dermatology. 1997; 36(Suppl 1): 7–10p.


Regular Issue Open Access Article
Volume 11
Issue 2
Received July 10, 2022
Accepted August 9, 2021
Published August 30, 2022